^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | DHES0815A (HER2-targeted antibody-drug conjugate, DNA replication inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo
Published date:
08/24/2021
Excerpt:
USC cell lines overexpressing HER2/neu were significantly more sensitive to DHES0815A...DHES0815A caused growth-inhibition and increased survival in USC HER2/neu overexpressing xenografts when compared to controls (p < 0.01). DHES0815A is both highly selective and toxic to USC tumors overexpressing HER2/neu both in vitro and in vivo.
DOI:
10.1016/j.ygyno.2021.08.014
Source:
Title:
911 - In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma
Published date:
03/10/2021
Excerpt:
High HER2/neu protein expression was seen in 25% (3/12) of the primary USC cell lines. USC cell lines overexpressing HER2/neu were significantly more sensitive to DHES0815A when compared to the non-targeted control ADC (p<0.001). DHES0815A caused growth-inhibition and increased survival in USC HER2/neu overexpressing xenografts when compared to controls (p<0.01)....DHES0815A is both highly selective and toxic to USC tumors overexpressing HER2/neu both in vitro and in vivo.
